Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹1551 Cr.
Stock P/E
-19.2
P/B
4.2
Current Price
₹696.3
Book Value
₹ 167
Face Value
10
52W High
₹936
52W Low
₹ 512.4
Dividend Yield
0%

Astec Lifesciences Overview

Business

Astec Lifesciences Ltd. is a leading Indian manufacturer of agrochemical active ingredients (AIs), intermediates, and pharmaceutical intermediates. The company primarily operates as a business-to-business (B2B) supplier, serving large domestic and international agrochemical and pharmaceutical companies. Its core business model involves leveraging its expertise in complex chemistries (e.g., organo-phosphorus, triazole, hydrazine chemistry) for custom synthesis and contract manufacturing operations (CMO), alongside producing proprietary active ingredients and intermediates. The company makes money by selling these manufactured products to its clients.

Revenue Mix

Astec Lifesciences primarily operates across three broad areas:

Agrochemical Active Ingredients: Manufacturing finished agrochemical products that are ready for formulation by clients.

Agrochemical Intermediates: Producing chemical compounds used as raw materials in the synthesis of more complex agrochemical active ingredients.

Contract Manufacturing & Custom Synthesis (CMO/CRAMS): Providing specialized manufacturing services to global agrochemical and pharmaceutical companies, often involving proprietary chemistries or exclusive arrangements for specific molecules. While specific revenue percentages are not readily available without external data, the company generally maintains a diversified mix between its proprietary products and growing custom synthesis business.

Industry

The company operates in the global Pesticides & Agrochemicals industry, which is characterized by high R&D intensity, strict regulatory frameworks, and increasing demand driven by population growth and the need for food security. The Indian market is a significant global hub for agrochemical manufacturing due to cost efficiencies and technical expertise. Astec Lifesciences positions itself as a specialized manufacturer, focusing on complex and niche chemistries that require significant technical know-how. It stands as a key supplier of intermediates and active ingredients to larger global players, often competing on technical capabilities, quality, and cost-effectiveness rather than brand in the end-user market. Being a subsidiary of Godrej Agrovet Ltd. provides it with strategic backing and synergies.

MOAT

Technical Expertise & Process Know-how: Specialization in complex and hazardous chemistries (e.g., handling hydrazine hydrate, triazole chemistry) creates high entry barriers and sticky customer relationships.

Backward Integration: Strategic backward integration into key raw materials or intermediates helps control costs, ensure supply security, and improve margins.

Customer Relationships & Trust: Long-standing relationships with large global and domestic agrochemical companies, particularly in contract manufacturing, often involve trust built over years of consistent quality and reliability.

Regulatory Compliance: Adherence to stringent environmental, health, and safety (EHS) standards and obtaining necessary regulatory approvals are critical in the chemical industry and serve as a barrier to new entrants.

Parentage: Being part of the Godrej Group (via Godrej Agrovet) provides financial stability, strong corporate governance, and potential synergistic advantages.

Growth Drivers

Increasing Global Food Demand: Drives demand for crop protection chemicals to enhance agricultural productivity.

Growth in Contract Manufacturing (CMO/CRAMS): Global agrochemical majors are increasingly outsourcing manufacturing to optimize costs and focus on R&D, creating opportunities for specialized players like Astec.

New Product Development & Registration: Successful development and commercialization of new active ingredients and intermediates can open new revenue streams.

Expansion into New Geographies/Markets: Tapping into underserved or growing international markets.

Backward Integration Initiatives: Further integration can improve cost structures and supply chain resilience.

Synergies with Godrej Agrovet: Potential for collaboration and preferred supplier status within the broader Godrej ecosystem.

Risks

Raw Material Price Volatility: Fluctuations in the prices of key chemical raw materials can impact production costs and margins.

Regulatory Risks: Changes in environmental regulations, pesticide registration norms, or import/export policies in India or client countries can affect operations and product viability.

Weather Dependency: Demand for agrochemicals is directly linked to agricultural output, which is highly dependent on weather conditions and monsoon patterns.

Intense Competition: Competition from domestic and international players, particularly from China, can put pressure on pricing and market share.

Forex Fluctuations: As a significant exporter and importer, the company is exposed to currency exchange rate volatility.

R&D Success Rate: The success of new product development is crucial, and R&D failures can lead to sunk costs without returns.

Client Concentration: Potential reliance on a few large clients for custom synthesis orders could pose a risk if those relationships falter.

Management & Ownership

Astec Lifesciences is promoted by the Godrej Group, a venerable Indian conglomerate, through its subsidiary Godrej Agrovet Ltd. Godrej Agrovet holds a significant majority stake, ensuring strong promoter backing and strategic alignment. The management team is generally professional and benefits from the strong corporate governance standards associated with the Godrej Group. The operational management is typically composed of experienced professionals from the chemical and agrochemical industries, responsible for driving technical expertise and operational efficiency.

Outlook

Astec Lifesciences operates in a fundamentally growing industry driven by global food demand and the increasing trend of outsourcing in the chemical sector. Its focus on specialized chemistries and contract manufacturing positions it well to capture growth opportunities. The strong backing of the Godrej Group provides stability and potential synergies. However, the company remains susceptible to inherent risks of the chemical industry, including raw material price volatility, stringent and evolving regulatory landscapes, and the vagaries of agricultural cycles. Its ability to continuously innovate, expand its product portfolio, and efficiently manage its cost structure will be key to sustaining growth amidst competitive pressures.

Astec Lifesciences Share Price

Live · BSE / NSE · Inception: 1994
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Astec Lifesciences Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 154 69 99 94 120 91 74 125 159 84
Other Income 2 1 2 2 1 1 1 1 3 1
Total Income 156 70 101 96 120 92 75 126 161 84
Total Expenditure 141 116 118 100 114 102 80 121 149 84
Operating Profit 15 -45 -18 -4 6 -10 -6 5 12 0
Interest 7 7 9 10 10 11 8 7 8 8
Depreciation 9 9 11 11 12 11 10 11 12 11
Exceptional Income / Expenses 0 0 0 0 0 0 0 -2 0 0
Profit Before Tax -1 -62 -39 -25 -16 -33 -24 -16 -8 -19
Provision for Tax 0 -22 0 15 0 0 0 0 -0 -0
Profit After Tax -1 -40 -39 -40 -16 -33 -24 -16 -8 -19
Adjustments -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Profit After Adjustments -1 -40 -39 -40 -16 -33 -24 -16 -8 -19
Adjusted Earnings Per Share -0.5 -20.1 -19.5 -20.4 -8.1 -16.7 -11 -7 -3.5 -8.4

Astec Lifesciences Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 247 299 368 431 523 555 677 628 458 381 448 442
Other Income 7 3 8 11 12 8 10 13 6 6 5 6
Total Income 254 302 376 442 535 563 687 641 464 387 453 446
Total Expenditure 215 236 299 354 437 443 522 552 464 448 453 434
Operating Profit 39 65 77 88 97 119 165 89 -0 -61 1 11
Interest 13 12 11 12 13 5 9 21 25 37 35 31
Depreciation 10 14 15 19 23 26 34 34 36 44 45 44
Exceptional Income / Expenses -3 -11 4 0 0 0 0 0 0 0 -2 -2
Profit Before Tax 12 29 56 56 61 89 121 35 -62 -141 -81 -67
Provision for Tax 7 10 21 20 14 24 31 9 -15 -6 -0 0
Profit After Tax 5 19 35 36 48 65 90 26 -47 -135 -81 -67
Adjustments -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 0
Profit After Adjustments 5 19 35 36 48 65 90 26 -47 -135 -81 -67
Adjusted Earnings Per Share 2.5 9.7 17.7 18.1 24.1 33 45.5 12.9 -23.8 -68.2 -36.3 -29.9

Astec Lifesciences Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 118 138 170 202 247 309 396 419 369 235 391
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 8 0 0 0 0 40 0 11 199 280 50
Other Non-Current Liabilities -2 1 5 9 6 6 38 23 9 6 1
Total Current Liabilities 203 194 238 249 318 322 491 526 397 366 500
Total Liabilities 328 334 413 461 572 678 925 979 975 887 942
Fixed Assets 95 103 115 167 194 213 340 318 386 499 459
Other Non-Current Assets 42 32 66 46 46 134 70 162 191 47 40
Total Current Assets 191 198 232 248 332 330 516 499 398 341 443
Total Assets 328 334 413 461 572 678 925 979 975 887 942

Astec Lifesciences Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 1 2 3 0 0 0 0 1 0 0 1
Cash Flow from Operating Activities -13 19 65 15 168 -8 24 75 10 -8 -81
Cash Flow from Investing Activities -16 -18 -49 -52 -74 -73 -104 -113 -135 -15 -4
Cash Flow from Financing Activities 31 -1 -18 37 -95 81 80 38 125 24 94
Net Cash Inflow / Outflow 2 1 -3 -0 0 0 0 -0 -0 0 9
Closing Cash & Cash Equivalent 2 3 0 0 0 0 1 0 0 1 10

Astec Lifesciences Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 2.53 9.73 17.74 18.14 24.1 32.97 45.52 12.95 -23.76 -68.21 -36.31
CEPS(Rs) 7.89 16.72 25.28 27.98 35.86 45.98 62.94 30 -5.39 -46.06 -16.14
DPS(Rs) 0 1.49 1.49 1.49 1.49 1.49 1.49 1.49 0 0 0
Book NAV/Share(Rs) 59.85 69.85 85.8 102.42 124.75 156.49 200.71 212.17 186.77 118.77 175.24
Core EBITDA Margin(%) 12.78 19.91 18.55 17.67 16.21 19.95 22.66 12.08 -1.29 -17 -1.01
EBIT Margin(%) 10.22 13.08 17.9 15.78 14.07 16.79 19.15 8.82 -7.95 -26.78 -10.37
Pre Tax Margin(%) 5.03 9.17 15.02 12.92 11.67 15.94 17.82 5.54 -13.45 -36.21 -18.07
PAT Margin (%) 2.05 6.12 9.45 8.27 9.04 11.64 13.22 4.05 -10.21 -34.6 -18.05
Cash Profit Margin (%) 6.26 10.49 13.41 12.74 13.45 16.24 18.28 9.39 -2.32 -23.37 -8.02
ROA(%) 1.47 5.8 9.38 8.18 9.2 10.42 11.21 2.69 -4.8 -14.47 -8.84
ROE(%) 4.01 15.07 22.9 19.31 21.24 23.46 25.5 6.28 -11.9 -44.64 -25.88
ROCE(%) 10.65 16.08 23.75 20.31 20.44 22.29 22.21 7.75 -4.5 -12.62 -5.71
Receivable days 136.14 111.38 115.06 103.32 98.14 113.66 123.7 123.89 128.71 148.32 160.92
Inventory Days 105.79 79.66 70.88 72.27 74.31 74.22 78.67 139.3 194.99 166.7 121.29
Payable days 176.72 126.85 121.9 106.55 143.21 176.37 150.04 166.93 152.31 105.03 103.52
PER(x) 76.38 61.59 32.54 29.47 16.47 30.12 38.22 106.02 0 0 0
Price/Book(x) 3.23 8.58 6.73 5.22 3.18 6.35 8.67 6.47 5.65 5.64 3.08
Dividend Yield(%) 0 0.25 0.26 0.28 0.38 0.15 0.09 0.11 0 0 0
EV/Net Sales(x) 2.03 4.35 3.43 2.85 1.68 3.87 5.49 4.85 5.62 4.92 3.66
EV/Core EBITDA(x) 12.9 19.92 16.37 14.01 9.06 17.95 22.56 34.14 -9579.67 -30.96 3007.12
Net Sales Growth(%) -7.45 20.92 23.07 17.23 21.28 6.17 21.93 -7.15 -27.06 -16.78 17.53
EBIT Growth(%) -0.75 62.42 61.97 2.87 8.3 26.88 38.76 -57.24 -165.61 -185.56 55.44
PAT Growth(%) -65.73 278.55 82.69 2.08 32.89 36.91 38.13 -71.53 -283.21 -187.29 39.96
EPS Growth(%) -66.39 283.78 82.44 2.26 32.84 36.78 38.07 -71.56 -283.54 -187.11 46.76
Debt/Equity(x) 1.08 0.92 0.74 0.87 0.4 0.61 0.71 0.81 1.34 2.36 1.15
Current Ratio(x) 0.94 1.02 0.97 1 1.04 1.03 1.05 0.95 1 0.93 0.89
Quick Ratio(x) 0.59 0.69 0.64 0.63 0.66 0.7 0.67 0.39 0.51 0.5 0.61
Interest Cover(x) 1.97 3.35 6.23 5.52 5.87 19.75 14.37 2.69 -1.45 -2.84 -1.35
Total Debt/Mcap(x) 0.33 0.11 0.11 0.17 0.13 0.1 0.08 0.13 0.24 0.42 0.37

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +18% -11% -4% +6%
Operating Profit CAGR — -78% -62% -31%
PAT CAGR — 0% 0% 0%
Share Price CAGR -1% -18% -11% +4%
ROE Average -26% -27% -10% +5%
ROCE Average -6% -8% +1% +11%

Astec Lifesciences Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 71.96 %
FII 0.01 %
DII (MF + Insurance) 3.33 %
Public (retail) 24.69 %
Others 0.01 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 66.7566.7566.7566.7570.8770.8772.4271.9771.9771.96
FII 1.251.030.531.20.250.0200.040.020.01
DII 7.883.384.514.634.344.264.013.173.343.33
Public 24.1128.8428.2127.4224.5424.8423.5724.8224.6724.69
Others 0000000000
Total 100100100100100100100100100100

Astec Lifesciences Peer Comparison

Pesticides & Agrochemicals Edit Columns

Astec Lifesciences Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Astec Lifesciences Pros & Cons

Pros

  • Debtor days have improved from 105.03 to 103.52days.
  • Company has reduced debt.

Cons

  • Company has a low return on equity of -27% over the last 3 years.
  • Stock is trading at 4.2 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp